The clinical verdict is consistent across every major trial: most people who stop GLP-1 medication regain two-thirds of their lost weight within one year. What follows is the evidence.
The STEP 1 Extension: What Happens After You Stop
The STEP 1 trial extension is the most comprehensive evidence for the GLP-1 rebound effect. After 68 weeks of semaglutide therapy with a mean weight loss of 17.3%, participants were transitioned to placebo and lifestyle guidance. Within 52 weeks of stopping, they had regained approximately two-thirds of that weight, returning to within 5.7% of their original body weight by week 120.
The mechanism is straightforward: semaglutide suppresses appetite by mimicking GLP-1, a hormone that signals fullness. When the drug leaves the body, appetite signals return to pre-treatment levels. Without behavioural infrastructure to support the reduced appetite, eating patterns revert within weeks.
STEP 1: Mean Body Weight Change Over 120 Weeks (%)
Source: Wilding JPH et al. STEP 1 Extension (2022). N=327 (semaglutide arm).
| Timepoint | Mean Weight Change | Treatment Status |
|---|---|---|
| Week 0 (baseline) | 0% | Semaglutide active |
| Week 20 | –8% | Semaglutide active |
| Week 40 | –14% | Semaglutide active |
| Week 68 (peak) | –17.3% | Final semaglutide dose |
| Week 80 | –12% | Post-discontinuation |
| Week 100 | –8% | Post-discontinuation |
| Week 120 | –5.7% | Post-discontinuation |
SURMOUNT-4: What Continued Treatment Proves
SURMOUNT-4 directly compared patients who continued tirzepatide (Zepbound/Mounjaro) versus those switched to placebo after 36 weeks. Both groups had lost approximately 20.9% of body weight at baseline. The divergence after that point is stark and clinically significant.
Patients who continued the medication achieved an additional 6.7% weight loss by week 88, reaching a cumulative 27.6%. Those who switched to placebo regained 14 percentage points by week 88, ending at just 6.9% below their original weight. In practice, this means more than two-thirds of their initial weight loss was gone within one year.
SURMOUNT-4: Cumulative Weight Loss (%) — Continued vs Discontinued
- Continued Tirzepatide
- Switched to Placebo
Source: SURMOUNT-4 Trial, Eli Lilly (2024). Aronne LJ et al.
| Timepoint | Continued Tirzepatide | Switched to Placebo | Difference |
|---|---|---|---|
| Week 36 (baseline) | –20.9% | –20.9% | 0% |
| Week 88 (outcome) | –27.6% | –6.9% | –20.7 percentage points |
| Change week 36 to 88 | –6.7% (further loss) | +14% (regain) | — |
Beyond the Scale: Metabolic Markers After Discontinuation
Weight is only one measure of the GLP-1 rebound. Clinical trials also tracked cardiovascular risk factors during and after treatment. The pattern is consistent across markers: benefits accumulate during active treatment and diminish after discontinuation, at varying rates.
Systolic and diastolic return toward baseline within 52 weeks of stopping medication.
Glycemic control shows the most resilience of any marker, but also declines after withdrawal.
Triglyceride and cholesterol improvements are largely lost upon weight regain.
Metabolic Health Score: During Treatment vs After Discontinuation
Index scale (0–100). Higher score = better clinical outcome.
- During Treatment
- Post Discontinuation
Synthesised from STEP 1 Extension and SURMOUNT-4 biomarker sub-analyses.
| Metabolic Marker | During GLP-1 Treatment | After Discontinuation | Reversal Rate |
|---|---|---|---|
| Systolic blood pressure | Significant reduction | Returns toward baseline | Rapid (within 52 weeks) |
| Diastolic blood pressure | Moderate reduction | Returns toward baseline | Rapid (within 52 weeks) |
| HbA1c (blood glucose) | Significant reduction | Partial return to baseline | Slower — most resilient marker |
| Triglycerides | Significant reduction | Largely reverses with weight regain | Fast |
| HDL cholesterol | Moderate improvement | Improvement mostly lost | Moderate |
| Insulin sensitivity | Substantial improvement | Diminishes with weight regain | Moderate to fast |
What the Evidence Means Clinically
Research from O'Neil et al. (2024) and the combined trial data point to three clinical realities that patients and practitioners need to understand before starting GLP-1 therapy.
GLP-1 medications work because obesity has a biological component. But treating a chronic condition with a temporary intervention produces temporary results. Short-term therapy does not resolve the metabolic drive to regain weight.
Emerging studies are exploring whether gradual dose reduction combined with rigorous lifestyle intervention can reduce the rebound effect. The evidence base is early and results are mixed.
Dietary intervention, resistance training, and psychological behaviour change are not optional add-ons to GLP-1 therapy. They are the mechanisms that determine whether weight loss is permanent after the drug stops.
The Behavioral Layer GLP-1 Cannot Provide
GLP-1 medications solve a biological problem: chronically elevated appetite signals that make reduced eating feel painful. When that signal is suppressed pharmacologically, eating less becomes easier. That is real and clinically meaningful.
What the drug does not change are the behavioural patterns, environmental triggers, and identity structures that drove weight gain in the first place. The eating cues are still there. The emotional associations with food are still there. The social and situational patterns are still there. The drug was suppressing your response to them. When the drug stops, those responses return.
This is not a failure of the medication. It is a gap in the model. GLP-1 drugs were designed to address appetite biology, not behaviour. Addressing behaviour requires a different system entirely.
Weight Permanence Training™ was built to close that gap. It works through five structured stages of awareness that surface the patterns, triggers, and identity questions that determine whether any weight loss is permanent. It is not a replacement for GLP-1 therapy. It is the behavioural infrastructure that determines what happens after the drug stops.